BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

When it comes to adding J.Crew styles to cart, the Moore the merrier. Demi Moore’s been wearing (and organically raving about) the brand’s classic designs for decades — and this month, she ...

The trial compared the ADC patritumab deruxtecan to chemotherapy in people with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) after the failure of a third ...

Imagine diving into the intricate world of business models, where every term, from “value proposition” to “value architecture,” plays a critical role in shaping how businesses create ...

Seagen won a lawsuit in April 2022 which claimed that Enhertu (trastuzumab deruxtecan) infringes a patient it holds (No. 10,808,039) covering antibody-drug conjugates that include auristatin ...

It was the second major licensing deal between the two companies, coming after the even-bigger $6.9 billion deal for HER2-directed ADC Enhertu (trastuzumab deruxtecan) in the previous year.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

While his main areas of expertise are maker tools -- 3D printers, vinyl cutters, paper printers, and laser cutters -- he also loves to play board games and tabletop RPGs. Expertise 3D printers ...

TA38 27 March 2002 27 March 2002 Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA34 15 March 2002 15 March 2002 Guidance on the use of fludarabine for B-cell chronic ...